Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Japan Receiving 90,000 Further Courses of MSD COVID-19 Pill Earlier than Scheduled
Health Minister Shigeyuki Goto said on February 4 that Japan will be receiving a further 90,000 courses of MSD’s oral COVID-19 pill Lagevrio (molnupiravir) earlier than initially scheduled in late February following negotiations with the manufacturer. Lagevrio earned special approval…
To read the full story
Related Article
- MSD Japan Boosts COVID-19 Pill Supply to 800,000 Courses by March
February 15, 2022
- MSD Moves Up Supply of 50000 Courses of Lagevrio to Japan
January 31, 2022
- MSD Japan Set to Supply 1.6 Million Courses of Lagevrio by September: President
January 26, 2022
- Japan Approves MSD’s Oral COVID-19 Drug Molnupiravir
December 27, 2021
- MSD’s Molnupiravir Up for PAFSC Review on Dec. 24
December 20, 2021
- MSD Files Oral COVID-19 Drug in Japan
December 3, 2021
- Japan to Receive 1.6 Million Courses of MSD’s COVID-19 Drug
November 11, 2021
REGULATORY
- Japan OKs Honebuto, Growth Strategy with Patented Drug Market Goals
July 21, 2026
- Takeda’s Oveporexton, Rhythm’s Imcivree Up for Japan Panel Review Aug. 3
July 21, 2026
- Japan’s Immunization Act Bill Set to Clear Diet after Session Extension
July 21, 2026
- Japan Eyes Early FY2027 Rollout of RSV Antibodies under NIP: Minister
July 21, 2026
- AMED-Backed R&D Yielded 31 Regulatory Approvals in FY2025
July 17, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…